🔗 Share this article The Global Health Body Sounds Concern Over Severe Scarcity of Weight-Loss Medications Under one in 10 people eligible to benefit from obesity jabs such as Wegovy can access them, caution the WHO as it releases its first guidance on the drugs. With in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just access to this class of drugs. Per projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken. "Our latest guidelines recognises that obesity is a lifelong illness that can be addressed with holistic and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and logistical bottlenecks are key hurdles to universal access to the treatments that can aid individuals in losing significant body mass, explains the organization. Weight-Loss Drug Supply Crisis Even in the current most optimistic outlook, the production of GLP-1 therapies could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO. The recommendation calls on countries and companies to expand access, by approaches including licensing agreements. A patent on the active ingredient – the core component of a leading brand – is due to expire in multiple nations in 2026. The Way Obesity Injections Function GLP-1 drugs mimick a natural hormone to delay gastric emptying, curb appetite and boost the sense of being full so users consume fewer calories. Patients commonly begin shedding pounds in the initial weeks of commencing the once-weekly jabs. Evidence indicates people may regain a significant portion a year later of discontinuing the treatment, when their normal appetite come back. Being carrying excess weight raises your chance for developing diseases, such as type 2 diabetes, heart disease, brain attack, and certain cancers. Excess weight concerns people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the WHO.
Under one in 10 people eligible to benefit from obesity jabs such as Wegovy can access them, caution the WHO as it releases its first guidance on the drugs. With in excess of 1,000,000,000 people worldwide now obese, it is calling for increased and just access to this class of drugs. Per projections, in excess of 2,000,000,000 could be obese by 2030 unless action is taken. "Our latest guidelines recognises that obesity is a lifelong illness that can be addressed with holistic and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and logistical bottlenecks are key hurdles to universal access to the treatments that can aid individuals in losing significant body mass, explains the organization. Weight-Loss Drug Supply Crisis Even in the current most optimistic outlook, the production of GLP-1 therapies could only cover approximately 100 million people – fewer than 10% of the global need, per the WHO. The recommendation calls on countries and companies to expand access, by approaches including licensing agreements. A patent on the active ingredient – the core component of a leading brand – is due to expire in multiple nations in 2026. The Way Obesity Injections Function GLP-1 drugs mimick a natural hormone to delay gastric emptying, curb appetite and boost the sense of being full so users consume fewer calories. Patients commonly begin shedding pounds in the initial weeks of commencing the once-weekly jabs. Evidence indicates people may regain a significant portion a year later of discontinuing the treatment, when their normal appetite come back. Being carrying excess weight raises your chance for developing diseases, such as type 2 diabetes, heart disease, brain attack, and certain cancers. Excess weight concerns people in countries worldwide and was linked to millions of fatalities worldwide in 2024, per the WHO.